Shein Shares Slide 9% in Hong Kong IPO Debut 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
France Targets Shein, Temu With Fast-Fashion Fees 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Rejects Apple Trade Secret Theft Claims 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
WALTHAM, Mass., March 19, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 17th Annual Healthcare Conference on, March 28, 2018 at 11:00 AM EDT at the Westin Grand Central Hotel in New York, NY.
To access a live audio webcast of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
